Latest Headlines

Latest Headlines

DARPA to back research on peripheral nerve stimulation to boost brain plasticity, learning

The U.S. Defense Advanced Research Projects Agency (DARPA) would like to help create an external device that can be used for targeted neuroplasticity training (TNT).

Gilead using iRhythm patch in late stage trial for novel hypertrophic cardiomyopathy candidate

Biopharmas are interested in incorporating wearables that offer continuous patient monitoring into clinical trials of their drug candidates. But it's still early in terms of understanding of how these sorts of data can be used--and what regulators will make of them.  

Amgen's bone drug 'romo' fails to excite in male osteoporosis

Analysts remain skeptical of Amgen's new osteoporosis treatment romosozumab as the Big Biotech releases new data ahead of a potential filing in the next year.

UPDATED: Atlantic Healthcare closes $24M round and gains Salix founder as new CSA

Atlantic Healthcare has raised $24 million in its latest financing, with the founders of Salix Pharmaceuticals and Clinigen Group stumping up much of the cash and Dr. Lorin Johnson joining the company's leadership team.

Merck's $20M-plus Harvard deal offers a lesson on the new Economics 101 of preclinical R&D;

Last fall, the folks behind Harvard's Blavatnik Biomedical Accelerator took a promising preclinical program from the lab of Matthew Shair and essentially posted a "for sale" sign on it--touting its potential for mounting a fresh line of attack on acute myeloid leukemia with a counterintuitive therapeutic strategy ready for the clinic. The move didn't escape Merck's attention.

J&J; highlights consumer devices, most investable 6 device segments in quest for growth

At the Barclays Global Healthcare Conference on March 17, Johnson & Johnson highlighted a consumer medical device focus, particularly in emerging markets, alongside 6 device areas of innovation that are expected to undergird growth in the segment for the conglomerate going forward.

BerGenBio secures a $25M capital raise for its first-in-class cancer drug

Fledgling Norwegian biotech BerGenBio has raised 212 million kroner ($25 million) in a private placement from existing shareholders to help pay for new clinical trials for its lead treatment in blood and lung cancers.

What's next for Gilead in oncology?

As competition for its hepatitis C drugs intensifies, Gilead Sciences has been working to build up in other therapeutic areas, especially cancer. And while a painful clinical failure for the blockbuster hopeful Zydelig and the high-profile departure of oncology head Philippe Bishop have hamstrung those efforts, Gilead is bullish about its future in the field.

Roche, Kite Pharma sign CAR-T and PD-L1 combo deal

Roche and Kite Pharma are bringing together two of the hottest tickets in oncology research under a new deal announced this week.

NIH-developed dengue vaccine protects all patients in challenge study

As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.